Moleculin Historical Financial Ratios

MBRX
 Stock
  

USD 1.70  0.01  0.58%   

Moleculin Biotech is lately reporting on over 61 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value per Share of 3.01 will help investors to properly organize and evaluate Moleculin Biotech financial condition quickly. Financial Statement Analysis is infinitely more than just reviewing and investigating Moleculin Biotech recent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moleculin Biotech is a good buy for the upcoming year.
Additionally, see Stocks Correlation.
  

About Moleculin Financial Ratios Analysis

Moleculin BiotechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Moleculin Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Moleculin financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Moleculin Biotech history.

Moleculin Biotech Financial Ratios Chart

Moleculin Biotech CS financial ratios usually calculated using numerical values taken directly from Moleculin Biotech financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Moleculin Biotech. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
Moleculin Biotech Total Assets Per Share are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Assets Per Share of 2.94 in 2021. Net Current Assets as percentage of Total Assets is likely to rise to 88.37 in 2022, whereas Cash Flow Per Share is likely to drop (0.72)  in 2022.

Current Ratio

The ratio between Current Assets and Current Liabilities; for companies that operate a classified balance sheet.

Return on Average Assets

Return on assets measures how profitable a company is Net Income Common Stock relative to its total assets [AssetsAvg].

Return on Average Equity

Return on equity measures a corporation's profitability by calculating the amount of Net Income Common Stock returned as a percentage of [EquityAvg].

Return on Sales

Return on Sales is a ratio to evaluate a company's operational efficiency; calculated by dividing Earning Before Interest and Taxes EBIT by [Revenue]. ROS is often a component of DuPont ROE analysis.
Most ratios from Moleculin Biotech fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moleculin Biotech Total Assets Per Share are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Assets Per Share of 2.94 in 2021. Net Current Assets as percentage of Total Assets is likely to rise to 88.37 in 2022, whereas Cash Flow Per Share is likely to drop (0.72)  in 2022.

Moleculin Biotech fundamentals Correlations

-0.770.19-0.70.0-0.830.310.240.24-0.36-0.320.99-0.20.31-0.48-0.70.28-0.520.86-0.220.31
-0.770.180.990.350.77-0.20.050.050.410.39-0.75-0.17-0.20.020.47-0.240.81-0.640.12-0.2
0.190.180.170.980.30.250.910.910.790.830.29-1.00.23-0.810.380.030.69-0.050.050.24
-0.70.990.170.340.71-0.170.030.030.350.33-0.69-0.17-0.18-0.020.38-0.220.79-0.570.09-0.18
0.00.350.980.340.480.180.890.890.870.890.1-0.970.17-0.690.51-0.030.82-0.250.160.18
-0.830.770.30.710.48-0.20.290.290.750.71-0.78-0.27-0.210.190.88-0.280.8-0.940.48-0.2
0.31-0.20.25-0.170.18-0.20.240.240.060.080.33-0.261.0-0.32-0.10.940.00.25-0.121.0
0.240.050.910.030.890.290.241.00.720.750.33-0.890.23-0.640.340.040.58-0.090.220.24
0.240.050.910.030.890.290.241.00.720.750.33-0.890.23-0.640.340.040.58-0.090.220.24
-0.360.410.790.350.870.750.060.720.721.0-0.26-0.770.05-0.360.87-0.120.81-0.590.30.06
-0.320.390.830.330.890.710.080.750.751.0-0.21-0.810.07-0.430.83-0.10.81-0.540.260.08
0.99-0.750.29-0.690.1-0.780.330.330.33-0.26-0.21-0.30.33-0.54-0.620.28-0.440.83-0.220.33
-0.2-0.17-1.0-0.17-0.97-0.27-0.26-0.89-0.89-0.77-0.81-0.3-0.240.84-0.36-0.04-0.680.010.02-0.25
0.31-0.20.23-0.180.17-0.211.00.230.230.050.070.33-0.24-0.31-0.110.95-0.020.25-0.121.0
-0.480.02-0.81-0.02-0.690.19-0.32-0.64-0.64-0.36-0.43-0.540.84-0.310.1-0.14-0.38-0.460.4-0.32
-0.70.470.380.380.510.88-0.10.340.340.870.83-0.62-0.36-0.110.1-0.210.66-0.860.45-0.11
0.28-0.240.03-0.22-0.03-0.280.940.040.04-0.12-0.10.28-0.040.95-0.14-0.21-0.170.27-0.120.94
-0.520.810.690.790.820.80.00.580.580.810.81-0.44-0.68-0.02-0.380.66-0.17-0.580.14-0.01
0.86-0.64-0.05-0.57-0.25-0.940.25-0.09-0.09-0.59-0.540.830.010.25-0.46-0.860.27-0.58-0.650.25
-0.220.120.050.090.160.48-0.120.220.220.30.26-0.220.02-0.120.40.45-0.120.14-0.65-0.12
0.31-0.20.24-0.180.18-0.21.00.240.240.060.080.33-0.251.0-0.32-0.110.94-0.010.25-0.12
Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamentals Accounts

201720182019202020212022 (projected)
Cash Flow Per Share(2.05)(2.57)(2.26)(1.54)(0.66)(0.72)
Total Assets Per Share5.444.123.312.522.943.74
Net Current Assets as percentage of Total Assets31.2420.9139.2949.1881.9188.37
Book Value per Share5.533.312.291.82.943.01
Current Ratio3.752.063.785.8920.0221.6
Debt to Equity Ratio0.140.370.620.640.0650.0702
Earnings per Basic Share(3.18)(2.76)(1.95)(1.76)(0.59)(0.64)
Earnings per Diluted Share(3.18)(2.76)(1.95)(1.76)(0.59)(0.64)
Earnings per Basic Share USD(3.18)(2.76)(1.95)(1.76)(0.59)(0.64)
Enterprise Value over EBITDA(3.12)(1.66)(2.02)(2.17)1.41.5
Free Cash Flow per Share(2.38)(2.92)(2.54)(1.84)(0.71)(0.76)
Price to Book Value2.31.982.692.80.670.69
Price to Earnings Ratio(3.51)(2.26)(2.82)(2.72)(3.15)(3.4)
Return on Average Assets(0.48)(0.53)(0.49)(0.61)(0.17)(0.19)
Return on Average Equity(0.55)(0.71)(0.74)(1.1)(0.19)(0.21)
Return on Invested Capital7.155.522.8161.0712.2112.52
Tangible Assets Book Value per Share2.691.952.081.822.712.63

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
48.6 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.